Share Price & News Healthcare

AUD 299.59 -2.12 (0.703%)

(As on 2023-05-04 09:00:42 AEDT)
Previous Close Open Close* Market Capitalization Dividend Yield Day Range 52 WEEK HIGH LOW
$301.71 $300 $299.59 $144.51 B 1.12 $297.90 L $301.30 H $254.30 L $314.21 H

Chart Price & Info

Note: Kalkine Pty Limited (“Kalkine”) may display, include or make available third-party content including charts or any other data (“Third Party Content”) on its website/app. You acknowledge and agree that Kalkine is not responsible for Third Party Content including their accuracy, content, reliability or any other aspect thereof. Kalkine will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on such Third Party Content. All Third Party Content is the exclusive property of their respective owners.

Last Trade 299.59
Change% -0.7027
52 W H/L
EBITDA 3.54 B$
Net Profit
After Abnormals
$3.27 B
Capital $21.16 B
Return on Equity (ROE) 16.33%
Total Liabilities 19.99 B
Total Revenue 15.35 B
Cash 15.15 B

Stock Information*

Share price 299.59
Market Capitalization 144513006903
Price to Gross Cash Flow 33.21
Dividend Yield Excluding Special 1.18%
Diluted Share outstanding 481.71 M
Gross Dividend Per Share $3.2566
Dividend Yield 1.21%
Earnings Yield 2.170
Net Tangible Assets Per Share 35.98
PE Ratio --
Sector P/E --
Earnings per Share (EPS) (cents) 696.76
EV to EBITDA 24.53
Net Profit Margin 22.69%
Gross Cash Flow Per Share $8.31
Net Gearing -5.34%
Sales Per Share $32.43
Book Value Per Share $43.93

Similar Companies

About Company

CSL Limited develops, manufactures and markets human and veterinary pharmaceutical and diagnostic products derived from human plasma. The company markets its products - human and animal vaccines, antibiotics and anticoagulants – nationally and internationally. Recently the company has acquired Telecris in the US subject to regulatory approval. The Company is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and develops plasma products. Intellectual Property Licensing includes revenue and associated expenses from the licensing of Intellectual Property generated by the Group to unrelated third parties. Other Human Health consists of CSL Bio plasma and CSL Biotherapies. These businesses manufacture and distribute bio therapeutic products. It operates in four geographic areas: Australia, the United States of America, Switzerland, and Germany. Its subsidiaries include CSL Employee Share Trust, CSL Biotherapies Pty Ltd, Cervax Pty Ltd, CSL Biotherapies (NZ) Limited, Iscotec AB, Zenyth Therapeutics Pty Ltd, CSL International Pty Ltd and CSL Finance Pty Ltd.

Corporate Information

company address 45 Poplar Rd, Parkville, VIC, 3052

company phonePhone:   +61 3 9389 1911

company emailEmail:  [email protected]

company website Website:   www.csl.com.au

Event Calendar*

Event Type Event Date Event Year
Report (Interim) 2024-02-13 2024 upcoming
Report (Annual) 2023-09-01 2023
Report (Prelim) 2023-08-16 2023


© Data powered by Morningstar, Inc. 2023. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.